Professor Jacob Sherkow was quoted in an industry publication, BioPharma Dive, on what appears to be increased scrutiny from the FDA over gene therapies.
"[Gene therapy] was the third rail of FDA policies for a long time," Sherkow said. "They're a lot more open now. We have actual guidance about how to do this, how to do a clinical trial and what endpoints you should use."
Read the full article at biopharmadive.com.